Anavex Life Sciences Corp (AVXL)

[biotechnician]

Conference call highlights:
Parkinsons: Strong behavior response, cells actually grow back and reduction in inflammation
Alzheimers: Dr. Missling reports they held phase 2 studies to set up failure so they could find out without putting out tons of money or being unethical toward patient population, if the drug works. (Guess what it seems to work.) So phase 3 he says should always be , with the upcoming PK date, to CONFIRM phase 2 results. Sounded very confident.
Parkinson and Rhetts : Both foundations have never seen results like these before and thus helping to fund trials.
What is coming: Updates(plural) on the 104 week extension on Alzheimers Disease, PK/PD data, Rhetts phase 2. Parkinson phase2, AD phase 2/3 and possible results end of 2017 early 2018 on rhetts trial (only 12 week trial) same length on Parkinsons